

13. A pharmaceutical composition comprising a compound of formula (I), as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, and a pharmaceutically acceptable excipient.

14. A method of treating a disease or condition for which a JAK inhibitor is indicated, in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

15. A method of treating a disease or condition selected from allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of all types, chronic obstructive pulmonary disease, chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, exacerbation of airways hyper-reactivity consequent to other drug therapy, pulmonary vascular disease, pulmonary arterial hypertension, acute lung injury, bronchiectasis, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis or atopic dermatitis, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

16. A method of treating chronic obstructive pulmonary disease, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

17. A method of treating a disease or condition selected from inflammation, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematosus arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, Alzheimer's disease, skin flushing, eczema, psoriasis,

atopic dermatitis and sunburn, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

18. A method of treating psoriasis, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.

13. A pharmaceutical composition comprising a compound of formula (I), as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, and a pharmaceutically acceptable excipient.

14. Use of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt in the manufacture of a medicament for the treatment of a disease or condition for which a JAK inhibitor is indicated.

15. Use of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt in the manufacture of a medicament for the treatment of a disease or condition selected from allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of all types, chronic obstructive pulmonary disease, chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, exacerbation of airways hyper-reactivity consequent to other drug therapy, pulmonary vascular disease, pulmonary arterial hypertension, acute lung injury, bronchiectasis, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis or atopic dermatitis.

16. Use of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease.

17. Use of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt in the manufacture of a medicament for the treatment of a disease or condition selected from inflammation, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematosus arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and

type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn.

18. Use of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt in the manufacture of a medicament for the treatment of psoriasis.